

HR 8177

RAISE Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 4, 2020

Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means

Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (Sep 4, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/8177>

Sponsor

Name: Rep. O'Halleran, Tom [D-AZ-1]

Party: Democratic • **State:** AZ • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bucshon, Larry [R-IN-8]	R · IN		Sep 4, 2020
Rep. Butterfield, G. K. [D-NC-1]	D · NC		Sep 4, 2020
Rep. Mullin, Markwayne [R-OK-2]	R · OK		Sep 4, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	Sep 4, 2020
Ways and Means Committee	House	Referred To	Sep 4, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 4, 2020)

Renal Anemia Innovation Support and Expansion Act or the RAISE Act

This bill allows coverage of prescription vitamin and mineral products under the Medicare prescription drug benefit if the products are administered orally and are used to treat iron deficiency anemia in individuals who have chronic kidney disease.

Actions Timeline

- **Sep 4, 2020:** Introduced in House
- **Sep 4, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.